A Study of Tividenofusp Alfa (DNL310) in Pediatric Participants With Hunter Syndrome
- Registration Number
- NCT04251026
- Lead Sponsor
- Denali Therapeutics Inc.
- Brief Summary
This is a multicenter, multiregional, open-label study to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme replacement therapy (ERT), designed to treat both the peripheral and CNS manifestations of Mucopolysaccharidosis type II (MPS II; Hunter syndrome).
Participants, whose physicians feel they are deriving benefit, will have the opportunity to be reconsented into a safety extension and then an open-label extension for continued evaluation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Male
- Target Recruitment
- 47
Inclusion Criteria
- Confirmed diagnosis of MPS II
- Cohort A: Participants aged ≥5 to ≤10 years with neuronopathic MPS II
- Cohort B: Participants aged ≥1 to ≤18 years with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype
- Cohort C: Participants aged <4 years with neuronopathic MPS II (this cohort can include participants ≥4 to ≤18 years of age if participant is a blood relative of a participant <4 years of age)
- Cohort D: Participants aged ≤18 years with non-neuronopathic MPS II or neuronopathic MPS II with preexisting hepatomegaly who have never taken standard-of-care ERT
- Cohort E: neuronopathic MPS II participants aged ≥6 years at screening, non-neuronopathic MPS II participants <6 or ≥17 years at screening, and neuronopathic MPS II participants ≥1 to ≤18 years at screening with a history of prior haematopoietic stem cell transplantation or gene therapy who have completed at least 48 weeks in Study DNLI-E-0001
- For participants receiving intravenous iduronate 2-sulfatase (IDS) ERT, tolerated a minimum of 4 months of therapy during the period immediately prior to screening.
Key
Read More
Exclusion Criteria
- Unstable or poorly controlled medical condition(s) or significant medical or psychological comorbidity or comorbidities that, in the opinion of the investigator, would interfere with safe participation in the trial or interpretation of study assessments
- Use of any CNS-targeted MPS II ERT within 3 months before study start for participants aged ≥5 years, and within 6 months before study start for participants aged <5 years
- Use of IDS gene therapy or stem cell therapy at any time (except for participants in Cohort E)
- Clinically significant thrombocytopenia, other clinically significant coagulation abnormality, or significant active bleeding, or required treatment with an anticoagulant or more than two antiplatelet agents
- Contraindication for lumbar punctures
- Have a clinically significant history of stroke, status epilepticus, head trauma with loss of consciousness, or any CNS disease that is not MPS II-related within 1 year of screening
- Have had a ventriculoperitoneal (VP) shunt placed, or any other brain surgery, or have a clinically significant VP shunt malfunction within 30 days of screening
- Have any clinically significant CNS trauma or disorder that, in the opinion of the investigator, may interfere with assessment of study endpoints or make participation in the study unsafe
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Cohort A tividenofusp alfa Dose escalation followed by a consistent dose level in participants with neuronopathic MPS II Cohort C tividenofusp alfa A consistent dose level in participants with neuronopathic MPS II Cohort E tividenofusp alfa A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II Cohort B tividenofusp alfa A consistent dose level in participants with non-neuronopathic MPS II, neuronopathic MPS II, or unknown phenotype followed by dose escalation in some participants. Cohort D tividenofusp alfa A consistent dose level in participants with non-neuronopathic MPS II or neuronopathic MPS II
- Primary Outcome Measures
Name Time Method Change from baseline in urine total glycosaminoglycan (GAG) concentrations 24 weeks, 104 weeks, and 261 weeks Incidence and severity of infusion-related reactions (IRRs) 24 weeks, 104 weeks, and 261 weeks Incidence and severity of treatment-emergent adverse events (TEAEs) 24 weeks, 104 weeks, and 261 weeks Change from baseline in concomitant medications 24 weeks, 104 weeks, and 261 weeks
- Secondary Outcome Measures
Name Time Method Percentage change from baseline in cerebrospinal fluid (CSF) of heparan sulfate 24 weeks PK parameter: Trough concentration (Cmin) of DNL310 in serum 24 weeks Participants with improvement in individual disease progression in the Vineland Adaptive Behavior Scale Adaptive Behavior Composite (ABC) score 49 weeks Participants with improvement in individual disease progression in the Vineland Adaptive Behavior Scale subdomain scores 49 weeks PK parameter: Time to maximum observed concentration (tmax) of DNL310 in serum 24 weeks PK parameter: Area under the concentration-time curve over a dosing interval (AUCτ) of DNL310 in serum 24 weeks PK parameter: Apparent terminal elimination half-life (t½) of DNL310 in serum 24 weeks Percentage change from baseline in liver volume 24 weeks and 49 weeks PK parameter: Maximum observed concentration (Cmax) of DNL310 in serum 24 weeks PK parameter: Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUClast) of DNL310 in serum 24 weeks Characterization of immunogenicity of DNL310 in serum, as measured by the incidence of anti-drug antibodies (ADAs) relative to baseline 24 weeks PK parameter: Area under the concentration-time curve from time zero to infinity (AUC∞) of DNL310 in serum 24 weeks Percent change from baseline in urine concentration of heparan sulfate (HS) 24 weeks Participants with liver volume in the normal range 24 weeks and 49 weeks
Trial Locations
- Locations (7)
Erasmus Medical Center
🇳🇱Rotterdam, South Holland, Netherlands
UNC Children's Research Institute
🇺🇸Chapel Hill, North Carolina, United States
UCSF Benioff Children's Hospital
🇺🇸Oakland, California, United States
UPMC | Children's Hospital of Pittsburgh
🇺🇸Pittsburgh, Pennsylvania, United States
McGill University Health Centre - Royal Victoria Hospital
🇨🇦Montréal, Quebec, Canada
St Mary's Hospital, Manchester Academic Health Science Centre
🇬🇧Manchester, United Kingdom
Ann & Robert H. Lurie Children's Hospital of Chicago
🇺🇸Chicago, Illinois, United States